Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2011) G. Gutierrez-Garcia et al.   BLOOD

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

(2011) Francisco J. Hernandez-Ilizaliturri et al.   CANCER

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY

A Novel Method of Amplification of FFPET-Derived RNA Enables Accurate Disease Classification with Microarrays

(2010) P. Mickey Williams et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma

(2010) Shahab Uddin et al.   LABORATORY INVESTIGATION

Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores

(2010) Alexandar Tzankov et al.   LEUKEMIA & LYMPHOMA

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment

(2009) Zu-Guang Xia et al.   ANNALS OF HEMATOLOGY

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era

(2009) Ritsuko Seki et al.   CANCER SCIENCE

A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy

(2009) W. W.L. Choi et al.   CLINICAL CANCER RESEARCH

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

(2009) Heidi Nyman et al.   MODERN PATHOLOGY

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma

(2009) S. Hailfinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery

(2008) E. S. Jaffe et al.   BLOOD

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

(2008) L. M. Rimsza et al.   BLOOD

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

(2008) Kai Fu et al.   JOURNAL OF CLINICAL ONCOLOGY

Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)

(2008) D. de Jong et al.   JOURNAL OF CLINICAL PATHOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab

(2007) Yasodha Natkunam et al.   JOURNAL OF CLINICAL ONCOLOGY